Intraductal Radiofrequency Thermoablation and Radiotherapy Combined Treatment for Extrahepatic Cholangiocarcinoma
Intraductal Radiofrequency Thermoablation and Radiotherapy Combined Treatment for Extrahepatic Cholangiocarcinoma: A Prospective, Single-arm, Multicenter Study
National Cancer Center, Korea
53 participants
Apr 1, 2024
INTERVENTIONAL
Conditions
Summary
\[Study objectives\] To evaluate the efficacy and safety of the combined treatment of radiotherapy and endoscopic intraductal radiofrequency ablation in patients with locoregional extrahepatic cholangiocarcinoma.
Eligibility
Inclusion Criteria2
- Patients 20 years of age or older, who voluntarily agree to participate in the study and sign the informed consent.
- Patients with cytopathologically diagnosed inoperable extrahepatic cholangiocarcinoma
Exclusion Criteria6
- Patients who refuse to sign the informed consent
- Patients with metastatic cancer (stage IV) or malignant ascites
- Patients with intrahepatic cholangiocarcinoma
- Patients who are unable to undergo endoscopic procedures as determined by the investigator.
- Patients with a life expectancy of 3 months or less
- Patients with ID-RFA contraindications: pacemaker, pregnancy, uncorrected bleeding tendency (PT INR \> 1.5, platelets \< 50,000/mm3)
Interventions
The histologic or cytologic examination will be performed at the time of the first biliary drainage, and the extent of the cholangiocarcinoma lesion will be assessed during the procedure. After the diagnosis of extrahepatic cholangiocarcinoma, ID-RFA will be performed, and a biliary stent will be inserted for biliary drainage. Radiotherapy will be performed within 1 month of ID-RFA.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06168292